Community Benefit Agreements: A Report for the City of East Cleveland

Dr. Beth Nagy, Assistant Lecturer of Urban Planning Practice at the Levin College, worked with her UST 489 Senior Seminar class to produce a report for the City of East Cleveland on community benefit agreements (CBAs). Students examined CBAs across major cities throughout the United States to provide the City of East Cleveland with case studies on the different ways CBAs are utilized in other communities, while exploring the successes and limitations such efforts have encountered. The final report was presented to East Cleveland Mayor Brandon L. King in February 2020

Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction

Although percutaneous coronary intervention restores optimal epicardial blood flow in most cases, abnormal myocardial perfusion may still persist. This might be as a result of macro and microembolization, neutrophil plugging, vasoconstriction, myocyte contracture, local intracellular and interstitial edema, intramural haemorrhage, and endothelial blistering. Local delivery of intracoronary pharmacotherapy via the coronary arteries may increase local drug concentration several fold, and may improve drug efficacy. Several pharmacological agents such as adenosine, calcium channel blockers, alpha blockers, beta(2) receptor activators, vasodilators, antithrombotics, and antiplatelet agents have been used to treat coronary microvascular dysfunction. This article reviews the results of trials of intracoronary pharmacotherapy to date

Community Benefit Agreements: A Report for the City of East Cleveland

Dr. Beth Nagy, Assistant Lecturer of Urban Planning Practice at the Levin College, worked with her UST 489 Senior Seminar class to produce a report for the City of East Cleveland on community benefit agreements (CBAs). Students examined CBAs across major cities throughout the United States to provide the City of East Cleveland with case studies on the different ways CBAs are utilized in other communities, while exploring the successes and limitations such efforts have encountered. The final report was presented to East Cleveland Mayor Brandon L. King in February 2020

Use of the TIMI frame count in the assessment of coronary artery blood flow and microvascular function over the past 15 years

Since its introduction, the TIMI frame count method has contributed to the understanding of the pathophysiology of coronary artery disease. In this article, the evolution of the TFC method and its applicability in the assessment of various therapeutic modalities are described

Transfusion associated microchimerism: a heretofore little recognized complication following transfusion

Potent antiplatelet and antithrombotic agents have significantly reduced mortality in the setting of acute coronary syndromes and percutaneous coronary intervention. However these agents are associated with increased bleeding which is in turn associated with adverse clinical outcomes. In many centers, transfusion is often used to correct for blood loss. Blood transfusion in the setting of acute coronary syndrome has been associated with adverse clinical outcomes including increased mortality. Transfusion associated microchimerism (TA-MC) is a newly recognized complication of blood transfusion. There is engraftment of the donor's hematopoietic stem cells in patients who then develop microchimerism. This article discusses the association of bleeding/blood transfusion with adverse outcomes and the potential role of TA-MC in clinical outcomes

Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer

Abstract Patients with pancreatic cancer commonly develop weight loss and muscle wasting. Whether adipose tissue and skeletal muscle losses begin before diagnosis and the potential utility of such losses for earlier cancer detection are not well understood. We quantify skeletal muscle and adipose tissue areas from computed tomography (CT) imaging obtained 2 months to 5 years before cancer diagnosis in 714 pancreatic cancer cases and 1748 matched controls. Adipose tissue loss is identified up to 6 months, and skeletal muscle wasting is identified up to 18 months before the clinical diagnosis of pancreatic cancer and is not present in the matched control population. Tissue losses are of similar magnitude in cases diagnosed with localized compared with metastatic disease and are not correlated with at-diagnosis circulating levels of CA19-9. Skeletal muscle wasting occurs in the 1–2 years before pancreatic cancer diagnosis and may signal an upcoming diagnosis of pancreatic cancer